How Much Weight Can You Lose on Mounjaro?

It is the first question almost every patient asks. The honest answer: more than any other licensed medication in the UK, but results depend heavily on dose reached, dietary changes, and adherence.

What the clinical trials show

SURMOUNT-1 (Jastreboff AM et al, N Engl J Med 2022, n=2,539, 72 weeks) remains the landmark trial for tirzepatide in weight management:

For a patient starting at 100kg on the maximum dose, this represents an average loss of 22.5kg over 72 weeks, outcomes comparable to bariatric surgery in some analyses.

A week-by-week timeline

Weeks 1 to 4 (2.5mg)

The starting dose exists to allow adjustment. It is not a therapeutic weight loss dose. Most patients should not expect dramatic weight loss here. What to notice: reduced appetite, feeling full more quickly, possibly less food noise. Weight loss varies significantly between individuals at this stage, the mechanism is working from day one, but clinical effects accumulate over weeks and months.

Weeks 4 to 8 (5mg)

The first therapeutic dose. Appetite suppression becomes more pronounced. Most patients notice eating substantially less without feeling deprived. Weight loss tends to accelerate during this phase.

Weeks 8 to 20 (titration, 7.5mg, 10mg, 12.5mg)

The most consistent period. Each dose increase brings further appetite suppression. Patients often report the most dramatic reduction in food noise during this phase. Based on the overall 72-week SURMOUNT-1 trajectory, patients are typically making meaningful progress by this stage, though the exact pace varies considerably.

Weeks 20 to 36 (maintenance dose)

Most patients tolerating escalation have reached 12.5mg or 15mg. Weight loss continues but the rate often slows as the body adapts and a new weight setpoint is established. This is normal and represents sustainable progress.

Weeks 36 to 72 (consolidation)

Weight loss continues through week 72 in clinical trial data. Meaningful additional loss occurred between weeks 36 and 72 for patients who remained on treatment. Dietary and lifestyle habits built during earlier phases become most important here.

What makes the biggest difference to your results

1. The dose you reach: higher doses produce significantly more weight loss. Titrating slowly to minimise side effects is far preferable to stopping at a lower dose due to early discomfort.
2. Dietary changes: SURMOUNT-1 required participants to follow dietary guidance alongside medication. Patients who reduce calorie intake and prioritise protein achieve substantially better outcomes. Most weight loss pharmacists recommend 1,200 to 1,500 kcal/day for women and 1,500 to 1,800 kcal/day for men.
3. Physical activity: 150 minutes moderate activity per week per NHS guidance. Resistance training preserves lean muscle mass during significant calorie deficit.
4. Adherence: missing doses or stopping early significantly impairs outcomes. Mounjaro is a long-term treatment, not a short course.
5. Individual variation: genetics, gut microbiome, and baseline metabolic health all affect response. Weight loss plateau for more than 8 weeks at a stable dose warrants clinical review.

What about weight regain after stopping?

SURMOUNT-4 (Aronne LJ et al, JAMA 2024): after stopping tirzepatide following significant weight loss, patients regained approximately 14% of starting body weight over 52 weeks, but remained meaningfully lighter than their pre-treatment baseline.

This reflects the chronic, relapsing nature of obesity as a disease. Many patients benefit from ongoing treatment, similar to long-term antihypertensive therapy. This is not a failure. It is biology.

"Based on clinical evidence, most patients can expect 5% to 8% weight loss within 12 weeks, and 15% to 22% by week 72 at therapeutic doses, alongside significant improvements in blood pressure, blood sugar, and lipid profiles."